NCT00965991

Brief Summary

Our hypothesis is that metformin and glyburide will have equal efficacy in controlling blood glucose in gestational diabetics with no increase in adverse maternal, fetal or neonatal outcomes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
149

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2003

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2003

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2008

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

August 24, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 26, 2009

Completed
13.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2023

Completed
5 months until next milestone

Results Posted

Study results publicly available

December 21, 2023

Completed
Last Updated

November 19, 2024

Status Verified

October 1, 2024

Enrollment Period

4.8 years

First QC Date

August 24, 2009

Results QC Date

August 23, 2023

Last Update Submit

October 28, 2024

Conditions

Keywords

Gestational diabetesMetforminGlyburideoral agents

Outcome Measures

Primary Outcomes (1)

  • Number of Participants Assessed for Glucose Control

    The importance of exercise in the management of blood glucose was emphasized, and 30 minutes of walking per day was recommended. Patients received instruction from a nurse educator or a certified diabetes educator regarding diet and the use of the glucometer. Number of participants with a glucose level \<100 mg/dL.

    fasting and 2 hour postprandial blood glucose

Study Arms (2)

Metformin

ACTIVE COMPARATOR
Drug: metformin

Glyburide

ACTIVE COMPARATOR
Drug: Glyburide

Interventions

patients received glyburide initial dose of 500 mg PO BID. Increased as necessary to a maximum dose of 2000 mg QD to control blood glucose

Also known as: Glucophage
Metformin

Initial dose of 2.5mg PO BID increased as necessary to a maximum dose of 20 mg (10mg BID) QD to control blood glucose

Also known as: sulfonylurea
Glyburide

Eligibility Criteria

Age13 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Gestational diabetes not controlled with diet and exercise

You may not qualify if:

  • history of alcohol misuse
  • history of drug misuse
  • Chronic hypertension requiring medication
  • Renal failure
  • Hepatic disease or dysfunction
  • Known fetal anomaly
  • Inability to give consent
  • known allergy to metformin or glyburide

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of New Mexico Diabetes in Pregnancy Clinic

Albuquerque, New Mexico, 87131, United States

Location

Related Publications (1)

  • Moore LE, Clokey D, Rappaport VJ, Curet LB. Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstet Gynecol. 2010 Jan;115(1):55-59. doi: 10.1097/AOG.0b013e3181c52132.

MeSH Terms

Conditions

Diabetes, Gestational

Interventions

MetforminGlyburideSulfonylurea Compounds

Condition Hierarchy (Ancestors)

Pregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

BiguanidesGuanidinesAmidinesOrganic ChemicalsUreaAmidesSulfonesSulfur Compounds

Results Point of Contact

Title
Lisa Moore
Organization
University of New Mexico

Study Officials

  • Lisa E Moore, MD

    University of New Mexico

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 24, 2009

First Posted

August 26, 2009

Study Start

July 1, 2003

Primary Completion

May 1, 2008

Study Completion

August 1, 2023

Last Updated

November 19, 2024

Results First Posted

December 21, 2023

Record last verified: 2024-10

Locations